Anandamide suppresses proliferation and cytokine release from primary human T-lymphocytes mainly via CB2 receptors.
BACKGROUND
Anandamide (AEA) is an endogenous lipid mediator that exerts several effects in the brain as well as in peripheral tissues. These effects are mediated mainly by two types of cannabinoid receptors, named CB(1)R and CB(2)R, making AEA a prominent member of the "endocannabinoid" family. Also immune cells express CB(1) and CB(2) receptors, and possess the whole machinery responsible for endocannabinoid metabolism. Not surprisingly, evidence has been accumulated showing manifold roles of endocannabinoids in the modulation of the immune system. However, details of such a modulation have not yet been disclosed in primary human T-cells.
In this investigation we used flow cytometry and ELISA tests, in order to show that AEA suppresses proliferation and release of cytokines like IL-2, TNF-alpha and INF-gamma from activated human peripheral T-lymphocytes. However, AEA did not exert any cytotoxic effect on T-cells. The immunosuppression induced by AEA was mainly dependent on CB(2)R, since it could be mimicked by the CB(2)R selective agonist JWH-015, and could be blocked by the specific CB(2)R antagonist SR144528. Instead the selective CB(1)R agonist ACEA, or the selective CB(1)R antagonist SR141716, were ineffective. Furthermore, we demonstrated an unprecedented immunosuppressive effect of AEA on IL-17 production, a typical cytokine that is released from the unique CD4+ T-cell subset T-helper 17.


CONCLUSIONS
Overall, our study investigates for the first time the effects of the endocannabinoid AEA on primary human T-lymphocytes, demonstrating that it is a powerful modulator of immune cell functions. In particular, not only we clarify that CB(2)R mediates the immunosuppressive activity of AEA, but we are the first to describe such an immunosuppressive effect on the newly identified Th-17 cells. These findings might be of crucial importance for the rational design of new endocannabinoid-based immunotherapeutic approaches.
Cencioni
Maria Teresa
MT
European Center for Brain Research (CERC)/Santa Lucia Foundation, Rome, Italy.
Chiurchiù
Valerio
V
Catanzaro
Giuseppina
G
Borsellino
Giovanna
G
Bernardi
Giorgio
G
Battistini
Luca
L
Maccarrone
Mauro
M
D001095:Arachidonic Acids / Q000494:pharmacology*; D001483:Base Sequence; D001892:Camphanes / Q000494:pharmacology; D049109:Cell Proliferation / Q000187:drug effects*; D016207:Cytokines / Q000378:metabolism*; D017931:DNA Primers; D063388:Endocannabinoids; D004797:Enzyme-Linked Immunosorbent Assay; D005434:Flow Cytometry; D006801:Humans; D018613:Microscopy, Confocal; D010880:Piperidines / Q000494:pharmacology; D053284:Polyunsaturated Alkamides / Q000494:pharmacology*; D011720:Pyrazoles / Q000494:pharmacology; D043885:Receptor, Cannabinoid, CB2 / Q000819:agonists / Q000378:metabolism*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D000077285:Rimonabant; D013601:T-Lymphocytes / Q000187:drug effects* / Q000378:metabolism
D001095:Arachidonic Acids; D001892:Camphanes; D016207:Cytokines; D017931:DNA Primers; D063388:Endocannabinoids; D010880:Piperidines; D053284:Polyunsaturated Alkamides; D011720:Pyrazoles; D043885:Receptor, Cannabinoid, CB2; C110630:SR 144528; D000077285:Rimonabant; C078814:anandamide